From device actuation to deposition and beyond
Nasal drug delivery is evolving. As developers explore new therapeutic targets, formulations and delivery technologies, understanding what leaves the device is only part of the challenge. Discussions at IPAC-RS NIF 2026 highlighted a broader question:
How do we connect device performance with where the dose goes and what happens when it gets there?
Successful nasal delivery can mean different things for different products. Broad nasal coverage may be appropriate for one therapy, while another may depend on reaching a specific region of the nasal cavity. For complex formulations such as biologics, developers may also need to understand whether the drug remains in the intended condition following delivery. This creates an increasingly connected testing journey:
Actuation → Spray Characterization → Regional Deposition → Sample Recovery → Analysis
Anatomy is part of the experiment
Regional deposition is influenced not only by the device and formulation, but also by nasal anatomy and administration technique. Nasal casts can help researchers explore these relationships, but reproducible positioning matters. Insertion depth, nozzle angle, device orientation, and cast alignment can all influence the experiment. Creating a repeatable connection between the device, actuator, and anatomical model is therefore an important foundation for meaningful deposition studies.
New devices require new testing approaches
Today’s nasal delivery landscape includes conventional sprays alongside powders, soft-mist technologies, targeted delivery systems, and devices that incorporate patient airflow. These technologies may require different approaches to actuation, airflow control, positioning, and characterization. The goal is not simply greater flexibility. It is to build an experimental approach around the specific development question the researcher needs to answer.
What happens after delivery?
For emerging and complex formulations, deposition may not be the end of the investigation.
Knowing that a formulation reached a particular region does not necessarily tell us what arrived there. Connecting controlled delivery and regional sample recovery with appropriate downstream analysis can provide a more complete picture of product performance.
At Proveris, we see an opportunity to help researchers follow that journey further, connecting how a dose is delivered, where it goes, and what can be learned from it after delivery.
From measurement to understanding
IPAC-RS NIF 2026 reinforced an important principle: no single measurement tells the entire story. By connecting precise actuation, established spray characterization, anatomical testing, sample recovery and appropriate downstream analysis, we can build a stronger understanding of nasal drug delivery from device to destination.
Follow the dose. Understand the journey.
Explore Proveris solutions for nasal drug delivery testing
Spray Characterization Testing – Proveris Laboratories
Want to dig deeper? Download our article, Inside the Spray: How In Vitro Tools Reveal What’s Really Happening When Your Product Meets a Patient, to explore how in vitro tools can reveal more about the interaction between your product, device, and the patient.
Download the article

